The longest follow-up study data in the phase III clinical trial of first-line treatment of lung cancer in tumor immunotherapy.

Mercedon released its key Phase III clinical trial KEYNOTE-024 study on September 29th with five-year survival data.
The study was designed to assess the effectiveness and safety of patients with the first-line treatment of PD-L1 expression-positive (TPS≥50%), the metastatic non-small cell lung cancer (NSCLC) patients with mesadon PD-1 inhibitor Paboliju monoantigenic psoriasis (TPS≥50%), the genetic mutation-negative and mesolytic lymphoma kinase (ALK) of the skin growth factor (EGFR).
this is the longest follow-up data in the phase III clinical trial of the first-line treatment NSCLC, and the first published five-year survival data.
Lung cancer is one of the most important malignant tumors threatening the health of the residents of our country, the latest statistics released by the National Cancer Center show that in 2015 there were about 787,000 new lung cancer patients in China, and the death toll was about 631,000, ranking first in the incidence and death of malignant tumors in China.
According to the Regulations for the Diagnosis and Treatment of Primary Lung Cancer (2018 Edition), non-small cell lung cancer (NSCLC) accounts for about 80% to 85%, and the five-year survival rate of patients with late NSCLC in China is only about 5%, and the treatment status quo needs to be improved urgently.
, the five-year survival rate for patients with advanced NSCLC in the United States was only 5 per cent," says Dr Martin Reck of the Great Hansdorf Lung Clinic, a German lung research centre.
The long-term survival benefits of Pabliju monotherapy demonstrated in the KEYNOTE-024 study are another milestone in the development of lung cancer treatment, providing patients with longer disease-free progression times and the possibility of living longer.
The publication of the five-year survival data from the KEYNOTE-024 study further enhances our understanding of the important role that Pablo's monoigen resistance plays in lung cancer treatment," said Dr. Roy Baynes, Senior Vice President of Global Clinical Research and Chief Medical Officer of Mercer East Laboratories.
we would like to express our sincere gratitude to the patients and medical workers involved in KEYNOTE-024 and other Mercedon clinical trials who have played a critical role in driving the development of cancer treatment.
"The KEYNOTE-024 trial is the only phase III clinically proven five-year increase in the first-line treatment of advanced lung cancer in immunotherapy," said Professor Lu Wei, Director of Oncology At Shanghai Jiaoxuan University's Affiliated Chest Hospital. In patients with high expression of PD-L1, 31.9 percent of patients who used Pabliju monotherapy lived five years, and only 5 percent of patients who had previous chemotherapy years lived five years, six times as long as historical data, a remarkable advance.
the era of first-line immunotherapy for lung cancer, and is a landmark drug in the field of lung cancer treatment.
"KEYNOTE-024" study was presented on September 21st at the 2020 ESMO (European Society of Oncology) online conference.
To date, the adaptation certificate approved by the State Drug Administration (NMPA) for The Pabli Pearl monoantigen has been used for the treatment of non-removable or metastasis melanoma after a failed first-line treatment≥ The R/ALK gene mutated negative local late stage or metastatic NSCLC first-line single-drug therapy; and the combination carbalin and yew alcohol are suitable for metastatic squamous NSCLC first-line therapy; and the single drug is used to evaluate tumor expression PD-L1 (comprehensive positive score (CPS) ≥10) through fully validated testing, and for patients with previous first-line systemic treatment failure, local late stage or metastatic esophageal squamous cell carcinoma (ESCC).
.